Exit Menu

The role of the oncoprotein MYB in the head and neck cancer adenoid cystic carcinoma

Ongoing

Project description

Adenoid cystic carcinoma is characterised by slow but relentless growth that is only minimally affected by therapeutic treatments. Despite radio- and chemo-therapy, metastatic adenoid cystic carcinomas invariably progress until the patient succumb to the disease. In this research, we will investigate the role of the transcription factor and protooncogene MYB, frequently altered in adenoid cystic carcinoma, in promoting radio and chemo-resistance.

The central hypothesis that will be investigated is whether MYB gene rearrangements/overexpression in adenoid cystic carcinoma lead to activation of ATR, ATM, BUB1 and resistance to radiation and/or DNA damaging agents. A further aim will be to investigate whether disruption of the MYB > (ATR, ATM, BUB1) axis could cause enhanced sensitivity of cancer cells to radiation and/or chemotherapy, with the ultimate objective of improving treatment and survival of cancer patients.    

cancer-cells-541954_1920
cancer-cells-541954_1920
Please Allow all cookies to view this video from YouTube. Alternatively view the content here

Understanding adenoid cystic carcinoma

Professor Arturo Sala explains his research with the Oracle Cancer Trust